Back

Year-to-year change of antithrombotic strategy and clinical outcomes of atrial fibrillation patients with vascular disease in this decade: The Fushimi AF Registry.

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: From mobile health technology to clinical issues in atrial fibrillation Clinical ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Nobutoyo Masunaga

Kyoto Medical Centre, Kyoto (Japan)

6 More presentations in this session

Presentation thumbnail
The effect of a mobile health technology integrated care across multimorbidity patterns in atrial fibrillation patients: a latent-class ancillary analysis from the mAFA-II randomised clinical trial
Doctor B. Corica (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Mobile health technology integrated care in atrial fibrillation patients according to atrial fibrillation subtype: a subgroup analysis of the mAFA-II randomised trial
Doctor B. Corica (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Relationship of clinical complexity domains to management and outcomes of european and asian patients with atrial fibrillation: a comparison of two regional prospective observational AF registries
Doctor D. Mei (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Epidemiology and clinical impact of chronic obstructive pulmonary disease in patients with atrial fibrillation: findings from an european prospective observational registry
Doctor G. Romiti (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Predicting incident atrial fibrillation in patients with embolic stroke of undetermined source
Doctor P. Chousou (Cambridge, GB)
Abstract Slides Video

Access the full session

Session thumbnail
From mobile health technology to clinical issues in atrial fibrillation

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Interactive discussion and Q&A
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - discussion
thumbnail
Congress Presentation
Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources